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!Abstract 
ILegionella pneumophila, a microscopic bacterium usually 
/responsible for a number of illnesses and fatalities, can elimi-
/nate a local population, a region or even a nation. In 1976, L. 
Jpneumophila was first discovered due to a number of cases 
!presenting with pneumonia-like symptoms. These cases oc-
1curred in an isolated population attending an American Le-
l
gion convention in Philadelphia, Pennsylvania, therefore 
lending to the name Legionella. Usually found in aquatic en-
!vironments such as lakes, streams, cooling towers, air condi-
ltioning systems and hot tubs, its ability to thrive in artificial 
/and natural environments makes it an ideal bacterium. L. 
lpneumophila can be transmitted via inhaling aerosols that 
/contain the pathogen. After inhalation, the alveolar macro-
l
phages phagocytize the pathogen which then serves as its 
host Virulence factors such as lipopolysaccharides (LPS), are 
1one way the pathogen causes infection, however it can also 
/utilize heat shock protein and surface antigens. Usually with 
!Legionnaires' disease the physical symptoms consist of high 
!fever, malaise, muscle aches, rigors, confusion, headache and 
/diarrhea which categorizes this pathogen as causing an atyp-
lical pneumonia. Since L. pneumophila may be associated 
lwith travel-related infections, it is hard to track and isolate 
/travel-associated incident clusters because the symptoms 
Jpresent themselves after returning from travel. In regard to 
/diagnosis, this disease has five available techniques to con-
lfirm that the patient is in fact positive for L. pneumophila. 
!Programs such as the Environmental Legionella Isolation 
1Techniques Evaluation Program (ELITE) have been started 
!by the Centers for Disease Control and Prevention (CDC) in 
1order to decrease outbreak incidences. Additionally, the cur-
/rent recommendations for the management of Legionnaires' 
!disease adapted from the CDC have been summarized into a 
!flow chart which may help clinical decisions in the treatment 
1of this disease. 
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Introduction 
Legionnaires' disease, or Legionellosis, was first identified in 
1976 when an onslaught of pneumonia-like symptoms began 
in a group of individuals in attendance at an American Legion 
convention in Philadelphia.1 Since its first documented mani-
festation, Legionnaires' disease has remained relatively 
dormant. Recently, however, the respirato:ry illness has re-
turned to the spotlight as its abnormal instances of infection 
have been thoroughly covered by the news to alert the pub-
lic. In July 2015, an outbreak of Legionnaires' disease in the 
South Bronx of New York occurred.2 Investigation of this re-
cent outbreak has allowed scientists to trace the pathogen to 
its origin at the Opera House Hotel in the South Bronx. The 
same strain of bacteria responsible for the outbreak of Le-
gionnaires' disease was found on the cooling towers of the 
hotel. This was an overlooked location for disinfection and 
may be the reason behind the reoccurrence of the disease. 
Potential sources of Legionnaires' disease are often undetect-
ed until the disease manifests itself in symptomatic infected 
individuals. Furthermore, because patients present with fe-
ver, cough and diarrhea, symptoms that are common among 
many conditions, the disease presentation does not often 
provide a differential diagnosis.3 Laborato:ry diagnostics are 
utilized to confirm a case of Legionnaires' disease. The condi-
tion is classified as a notifiable disease by the Centers for 
Disease Control and Prevention (CDC) and, therefore, is sub-
ject to CDC protocol and intervention in the instance of an 
outbreak. Finally, with a recent increase in Legionnaires' dis-
ease, new policies have been set forth by the CDC to control 
as well as prevent future outbreaks. 
Etiology /Transmission 
Legionella pneumophila is the causative agent of Legion-
naires' disease. The microbe is a small, rod-shaped, gram-
negative, aerobic, intracellular bacterium.1 The variations in 
antigens that reside on the surface of the bacteria give rise to 
variations, or serogroups, of the microbe. Serogroup 1 is 
responsible for approximately 79 percent of infections in 
humans.4 Many diagnostic tools utilize the prevalence of 
serotype 1 as the primary source of infection to determine 
whether a patient has Legionnaires' disease or another type 
of respiratory infection. L. pneumophila resides in natural, as 
well as artificial, aquatic environments such as lakes, 
streams, cooling towers and air conditioning systems.s In a 
natural environment, the microbes reside as an intracellular 
parasite within protozoa.6 The microorganism thrives best in 
warm temperatures, at an optimal temperature of 35°C, and 
therefore it is prevalent in human synthesized water envi-
ronments where this temperature is maintained.4 The oppor-
tunistic, waterborne pathogen is transmitted via inhalation 
of aerosols. The bacterium is able to contaminate an aerosol, 
become airborne and easily access the respiratory system of 
a potential host. Aerosols are commonly in the form of sprays 
or mists. For instance, transmission may occur while an indi-
vidual is showering. This provides an opportunity for 
accidental inhalation. Likewise, an individual may become 
infected by inhaling contaminated water. It is also important 
to note that this particular pathogen is not transmitted from 
person to person. A droplet expelled from an infected indi-
vidual in the form of a sneeze or cough will not transmit the 
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pathogen. Therefore, contact with a patient infected by Le-
gionnaires' disease is not dangerous. Furthermore, most 
healthy people do not become infected with L. pneumophila 
after exposure. Risk factors include ages 50 years or older, 
current or former smokers, having a chronic lung disease, 
weakened immune system from diseases like cancer, diabe-
tes, or kidney failure, and taking medications that suppress 
the immune system.7 
The incidence of Legionnaires' disease in the United States 
has increased greatly since 1998. This may be attributed to a 
rise in the number of individuals in close proximity to con-
taminated water sources that have not been properly sani-
tized.B The increase, however, may also be due to greater 
access to diagnostic testing or an increase in the number of 
immunocompromised or at-risk individuals. This includes 
the elderly and those with weakened immune systems or an 
underlying illness.9 
Pathophysiology 
Once inhaled, the pathogen is phagocytized by alveolar mac-
rophages.to Attachment and entrance into the immune cells 
is thought to be complement independent and facilitated by 
the presence of pili. The microbe possesses the ability to es-
cape an immune response by preventing the formation of the 
phagolysosome utilizing a type 4 secretion system. There-
fore, the immune function of the macrophage is disabled. The 
intracellular bacterium then replicates depending on iron 
levels and the success of its various virulence factors. 
The virulence factors contributing to the body's response to a 
L. pneumophila infection are key elements in the bacterium's 
ability to enact an immune response. For example, lipopoly-
saccharide (LPS), heat-shock proteins as well as other sur-
face proteins serve as antigens, which are common to all 
gram-negative bacteria.11 Lipopolysaccharide is an endotoxin 
that signals the macrophage to release different pro-
inflammatory cytokines that produce an immune response. 
The cytokines that trigger the inflammatory response include 
tumor necrosis factor alpha (TNF-a.) and interleukin-1 (IL-1). 
T-lymphocytes target heat-shock proteins and produce anti-
bodies in response to their presence to promote the immune 
response. Furthermore, fluid extravasation is a characteristic 
of this immune response. When the response is signaled 
within the lung, fluid can occupy the air spaces thus causing 
pneumonia in progressive cases of Legionnaires' disease. 
Finally, once the bacterium has completed its replication pro-
cess, it can initiate apoptosis or necrosis of the macrophage. 
New bacteria are then released to infect other cells of the 
immune system to further its infective process. 
Signs/Symptoms 
L. pneumophila is classified as an atypical pneumonia.12 Pre-
sented symptoms, radiograph or x-ray results, and response 
to certain antibiotics may differ from typical bacteria that 
cause pneumonia by Streptococcus pneumoniae. Physical 
symptoms that are commonly observed in patients include 
high fever, malaise, muscle aches, rigors, confusion, headache 
and diarrhea.12,13 These symptoms may be followed by a 
nonproductive cough and shortness of breath. Symptoms 
usually present two to 10 days following exposure to the bac-
teria. However, patients should still be monitored for two 
weeks following exposure. Legionnaires' disease is also usu-
ally associated with hospital-acquired pneumonia and travel. 
Association with travel has been reported during the incuba-
tion period for more than 20 percent of cases reported to the 
CDC.7 Symptoms often do not present until after the person 
has returned from traveling from the source of infection, 
which makes detection of travel-associated clusters difficult. 
Diagnosis 
If an individual is suspected of having Legionnaires' disease, 
confirmation should be made with diagnostic testing. There 
are five available techniques for the diagnosis of Legion-
naires' disease.7 A urine antigen assay along with a culture of 
respiratory secretions is the preferred diagnosis method be-
cause both tests are 100 percent specific. Urine antigen assay 
allows for rapid, same day results but only tests for L. pneu-
mophilia serogroup 1. Respiratory cultures can take more 
than five days to provide a result but allow for comparison of 
clinical and environmental samples. Cultures may be affected 
by antibiotic therapies and must be obtained as soon as pos-
sible after a suspected diagnosis. Additionally, cultures de-
tect all species and serogroups of the bacteria. The following 
chart adapted from the CDC classifies the advantages and 
disadvantages for each diagnostic test (Table 1). 
After confirmation of Legionnaires' disease, steps must be 
taken to find the source of infection and inform the proper 
officials. Figure 1 provides a breakdown of the steps to diag-
nose a case of Legionnaires' disease.14 
Recent Outbreaks 
The World Health Organization (WHO) defines a disease out-
break as an "occurrence of cases of disease in excess of what 
would normally be expected in a defined community, geo-
graphical area or season."ts These occurrences may be con-
fined to one area or may span entire countries while lasting 
anywhere from days to several years. The CDC mentions that 
when two or more L. pneumophila exposed individuals occur 
at the same time and place and become sick as a result, a Le-
gionellosis outbreak has occurred.7 
In 2008, there were eight confirmed cases of a Legionnaires' 
disease outbreak at Saint Peter's University Hospital in New 
Jersey, resulting in three fatalities.16-10 All those infected had 
other underlying diseases that made them more susceptible 
to the L. pneumophila that was traced back to the hospital's 
water system. 
The Veteran Affairs Pittsburgh Healthcare System reported 
another L. pneumophila outbreak in October 2012.19 The 
CDC identified a total of 21 cases of Legionnaires' disease in 
this outbreak. This total was broken down into five definite 
and 16 probable health care-associated cases. There were 
five fatalities resulting from this outbreak, all within 30 days 
of a positive diagnostic test. 
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Table 1. Diagnostic Tests for Legionnaires' Disease.12 
Adapted from Centers for Disease Control and Prevention [Internet]. Atlanta (GA): U.S. Department of Health & Human Services. Atypical 
Pneumonia; [updated 2014 Feb 7; cited 2015 Nov 7]. Available from:www.cdc.gov/pneumonia/atypical/. 
Test Advantages Disadvantages 
Culture • Clinical and environmental isolates can • Technically difficult 
be compared • Slow (>5 days to grow) 
• Detects all species and serogroups • Sensitivity high dependent on technical skill 
• 100% specific • May be affected by antibiotic treatment 
Urine Antigen • Rapid (same day results) • Only 100% specific for L. pneumophilia serogroup 
1 (Lpl) 
0 Lpl may account for up to 80% of cases 
• Does not allow for molecular comparison to envi-
ronmental isolates 
Serology • Less affected by antibiotic treatment • Must have paired sera 
• 5-10% of population has titer 1 > 256 (no dis-
• 80-90% sensitive; 99% specific crimination between cases of Legionnaires' dis-
ease and other causes of community-acquired 
pneumonia) 
Direct • Can be performed on pathologic speci- • 25-75% sensitive 
Fluorescent mens 
Antibody (DFA) • > 95% specific 
Polymerase Chain • Rapid • Assays vary by laboratory and are not FDA-
Reaction (PCR) approved 
Figure 1. Process for Suspected Cases of Legionnaires' Disease.14 
Adapted from: Bartram J, Chartier Y, Lee JV, Bond K, Surman-Lee S. Legionella and the prevention oflegionellosis [Internet] . World Health 
Organization; 2007. Figure 9-1 p.143 [cited 2015 Nov 7]. Available from: www.who.int/water_sanitation_health/emerging/legionella.pdf. 
Suspect case 
of 
Legionnaires' 
Disease 
ConfirmL 
Pneumophila by 
urine, culture or 
serolo 
Positive result 
Report to local 
health officials-> 
obtain 2 week 
exposure history-> 
report case to CDC 
Health-care acquired: 
Search for other cases; 
Review hospital maintenance 
and risk management records 
Community acquired: 
Find source of 
infection 
Identify possible sources-> 
.,. _ __ "4 review maintenance records of 
Negative results 
No further action 
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One of the largest outbreaks occurred in July 2015 in the 
South Bronx in New York City.20 The source of contamination 
was found to be a cooling tower located on top of the Opera 
House Hotel. In this outbreak, 120 people were infected re-
sulting in 12 deaths. 
The most recent cases occurred in August 2015. The Illinois 
Department of Veterans' Affairs announced eight confirmed 
cases with no related fatalities.21 In this same time period, an 
outbreak also occurred in the San Quentin State Prison 
located in California where there were six confirmed cases.22 
Furthermore, a woman died after diagnosis in University 
Hospitals Case Medical Center in Cleveland, Ohio.23 A month 
later in Cleveland, Ohio, an employee at the NASA Glenn Re-
search Center was diagnosed with Legionnaires' disease. Alt-
hough there was no direct CDC response in these cases, the 
respective state health departments were involved. However, 
in some situations the CDC protocols for treating L. pneu-
mophila were used.23 
Response from Centers for Disease Control and Prevention 
In response to numerous outbreaks of L. pneumophila, the 
CDC started the Environmental L. pneumophila isolation 
Techniques Evaluation Program (ELlTE). its goal is to certify 
labs that are collecting and testing water samples for Le-
gionella. However, even with the ELITE certification, a lab is 
not automatically certified to eliminate the bacteria from the 
water. The CDC recommends that every outbreak should be 
treated independent from other cases. 24 
The CDC has kept a close eye on areas of natural disaster or 
warfare. These events lead to water systems becoming stag-
nant at room temperature. Since L. pneumophila bacterial 
growth thrives in temperatures of 35°C, these water systems 
become the ideal areas for Legionnaires' disease. The CDC 
has teamed up with the American Society of Heating, Refrig-
erating and Air-Conditioning Engineers (ASHRAE®) to com-
pile guidelines for treating and eradicating affected water 
systems. The final report, "ASHRAE Guideline 12-2000-
Minimizing the Risk of Legionellosis Associated with Building 
Water Systems," has served as the standard to eradicate L. 
pneumophila in affected water systems.zs. 26 
Management of Disease 
Current general recommendations for the management of 
Legionnaires' disease have been outlined in the flowchart in 
Figure 2.27 These include the early diagnosis, prompt treat-
ment with appropriate antibiotics and management of any of 
the possible respiratory, renal or CNS complications. This is 
key in identifying and managing Legionnaires' disease effec-
tively to predict the best patient outcomes. Patients present-
ing with community-acquired pneumonia (CAP) should be 
tested for Legionnaires' disease if they have failed a course of 
antibiotics for CAP, have severe symptoms requiring inten-
sive care, are immunocompromised, are from an environ-
ment with a Legionella outbreak or have a travel history 
within two weeks of the onset of symptoms. 
Jn cases of community-acquired pneumonia, the treatment 
guidelines are established via the Infectious Diseases Society 
of America and American Thoracic Society.2s These consen-
sus guidelines provide information on the diagnosis, empiri-
cal therapy and focused management of both inpatient and 
outpatient situations. For patients who are in the [CU, recom-
mendations for empiric antibiotics are a beta-lactam in addi-
tion to azithromycin or respiratory fluoroquinolone (cipro-
floxacin, levofloxacin, moxifloxacin). Once the L. pneumophi-
la is confirmed, the beta-lactam is no longer needed. Most 
patients recover from fever within three to five days, but 
therapy is continued for 10 to 14 days (five to 10 days for 
azithromycin), based on clinical stability (Table 2). In im-
munocompromised patients, therapy may be continued for 
as long as 21 days.14 
Conclusion 
Legionnaires' disease management, treatment and eradica-
tion come to the spotlight when outbreaks occur. Recent 
outbreaks throughout the United States have prompted the 
scientific community to learn more about how to earlier 
identify and fight Legionnaires' disease. With the use of pro-
grams like ELITE from the CDC and effective treatment pro-
tocols, health care professionals can effectively eradicate 
Legionnaires' disease while providing the best care to their 
patients. 
Figure 2. General Recommendations for Legionellosis Management.27 
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Table 2. Criteria for Clinical Stability.zs 
Patients should have no more than one of the following before discontinuation of antibiotics: 
0 Temperature s 37.8° C 
0 Heart rate s 100 beats/min 
0 
Respiratory rates 24 breaths/min 
Systolic blood pressure ~ 90mm Hg 
0 
0 
Arterial oxygen saturation 90% or p02 60mm Hg on room air 
Normal mental status 
Mandell LA. Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/ American Thoracic 
Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin lnfec Dis. 2007;44(Suppl 2):S27-S72. 
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